西格列汀与阿卡波糖治疗新诊断2型糖尿病患者的疗效比较

摘要

Objective To observe the efficacy of DPP-4 inhibitor sitagliptin for newly-diagnosed T2DM patients. Methods Forty T2DM patients were randomly assigned to 2 groups: group A receiving sitagliptin 100 mg and group B receiving acarbose 150 ~ 300 mg daily. Results After the 12-week treatment, the levels of HbAic FPG, 2 hPG, and body weight decreased significantly as compared to baseline in both groups, and there was no significant difference between the 2 groups (P>0. 05). HOMA-P increased significantly in the sitagliptin group (P<0. 01) and HOMA-IR and lipid profile were improved in the acarbose group (P<0. 05). Conclusion Sitagliptin is an effective and safe new medicine in reducing plasma glucose.%目的 观察DPP-4抑制剂西格列汀对新诊断T2DM患者的疗效.方法 40例新诊断的T2DM患者被随机分成两组,分别给予西格列汀和阿卡波糖单药治疗.结果 12周治疗后两组HbA1c、FPG、2 HPG及体重均明显减低,组间比较差异无统计学意义(P＞0.05).西格列汀组治疗后胰岛β细胞功能指数(HOMA-β)明显升高(P＜0.01),阿卡波糖组胰岛素抵抗指数(HOMA-IR)和血脂谱明显改善(P＜0.05).结论 西格列汀是一种安全有效的新型降糖药物.